Erlotinib is effective against FLT3‐ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn-Reference-Cited by-同舟云学术

Erlotinib is effective against FLT3‐ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn

Published:2020-06-15 Issue:8 Volume:34 Page:10182-10190
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Cao Zhi‐Xing¹,Guo Chuan‐Jie¹,Song Xiaominting¹,He Jun‐Lin¹,Tan Lu¹,Yu Si¹,Zhang Ruo‐Qi¹,Peng Fu²,Peng Cheng¹,Li Yu‐Zhi¹

Affiliation:

1. Pharmacy College Chengdu University of Traditional Chinese Medicine, The Ministry of Education Key Laboratory of Standardization of Chinese Herbal Medicine, Key Laboratory of Systematic Research, Development and Utilization of Chinese Medicine Resources in Sichuan Province‐Key Laboratory Breeding Base of Co‐founded by Sichuan Province and MOST Chengdu China

2. West China School of Pharmacy Sichuan University Chengdu China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201902922RR

Reference34 articles.

1. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non–small-cell lung cancer